Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
SB 242235
Cat. No.:
OB0225LY-0485
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
SB 242235 is a selective MAPK inhibitor that mainly acts on the p38 MAPK pathway to inhibit the cellular stress response.
Synonym:
SB-242235; SB242235; 193746-75-7; 4-(4-(4-Fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)-2-methoxypyrimidine; 4-[5-(4-Fluorophenyl)-3-piperidin-4-ylimidazol-4-yl]-2-methoxypyrimidine; 4-[5-(4-Fluoro-phenyl)-3-piperidin-4-yl-3H-imidazole-4-yl]-2-methoxy-pyrimidine
CAS No.:
193746-75-7
Compound CID:
9863367
Formula:
C19H20FN5O
Formula Weight:
353.39
Specification
Relative Density:
1.34 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
SB 242235 can be used to study the mechanisms of inflammatory response or play an important role in drug screening.
Library Information
Targets:
Kinases
Receptors:
p38 MAPK
Pathways:
MAPK; Autophagy
Plate Number:
AOCL-7
Plate Location:
c5
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
60 mg/mL; 169.78 mM
